Gene transfer technology {#Sec1}
========================

In 2004, the entire human genome was sequenced and over 25,000 genes were identified (Stein [@CR168]). Some of these initially uncharacterised genes have subsequently been identified, with many playing important roles in cellular development, maintenance and survival. Techniques that allow the study of these novel genes have therefore been instrumental in elucidating their function. Until relatively recently, gene expression could only be altered in post-mitotic neuronal cells using mouse transgenesis or microinjection of individual neurons in culture. However, the first adenoviral and Herpes gene transfer systems were highly effective at transducing neurons and could hence be used to study gene function in whole animal systems without developmental compensatory effects (Hermens and Verhaagen [@CR65]). Researchers were quick to see the potential of such systems and started to develop optimised vectors. An ideal gene delivery would: (1) transfer genes into both developing and mature animals; (2) transduce cells with high efficiency; (3) mediate high level, long-term expression; (4) cause limited cytotoxicity; (5) elicit a small/negligible immune response in vivo; (6) incorporate sufficient lengths of DNA so that transgenes of interest can be accommodated and (7) mediate regulatable expression. These characteristics are difficult to find in a single vector system, and hence, a variety of viral gene delivery systems have been developed, each with its own advantages and disadvantages (Table [1](#Tab1){ref-type="table"}). Table 1Viral vector systemsVectorEntryImmune responseCapacity (kb)LocationEase of productionExpressionRetrovirus (inc lentivirus)FusionMinimal8Integrates10^8^\*\*YearsAdenovirusReceptorBrisk\*\*\*36Episomal10^12^\*\*\*\*\*Weeks/monthsAAVReceptorNone4Integrates10^8^\*\*\*YearsHSVFusionBrisk\*\*\*\*30Episomal10^10^\*\*\*\*WeeksThe main characteristics of the four main viral vector systems being used to transfer genetic material into cells both in vitro and in vivo are compared above. Each system has been modified since their initial creation, enabling the capacity for the foreign transgene to be increase, especially in the case of adenoviral vectors where gutless vectors have a very large cloning capacity. The host immune response differs between each system, with retroviruses and AAV showing little or negligible immune response. In addition, these two systems facilitate long-term transgene expression. Adenoviral vectors have also shown increased longevity of transgene expression, especially when the promoter included in the viral cassette is modified from CMVAsterisks indicate the relative ease of production or the relative level of immune response, i.e. a greater ease of production or greater immune response elicited is represented by a higher score

Herpes simplex virus {#Sec2}
====================

Wild-type Herpes simplex virus (HSV) is a large double-stranded DNA virus that infects and replicates in the skin and mucous membranes. Due to the natural tropism of HSV, initial studies were performed on neurons (Ho and Mocarski [@CR67], [@CR68]). Many studies have now demonstrated long-term stable transgene expression in the nervous system (Glorioso and Fink [@CR53]), and preclinical studies on models of neurological disease, including glioma, peripheral neuropathy, chronic pain and neurodegeneration, show encouraging results (Cuchet et al. [@CR30]). Wild-type HSV is taken up by sensory nerve terminals and transported by retrograde axonal transport to dorsal root ganglion neurons where they may enter the lytic cycle or establish a latent state from which the virus may subsequently reactivate and spread. The HSV vector systems therefore mimic this latent state, producing a highly infectious, efficient vehicle for the delivery of exogenous genetic material to cells. The straightforward production of high-titre, pure preparations of non-pathogenic HSV vectors, known as amplicon vectors (Cuchet et al. [@CR30]), was achieved by introducing null mutations into viral immediate early genes. This readily disrupts the capacity for viral replication, but enables production of the vectors by in vitro complementation of these genes in *trans*. When used to transduce cells, these HSV vectors cause a latent-like infection in both neural and non-neural tissue. Further details on HSV vecterology can be found in reviews by Epstein et al. (Cuchet et al. [@CR30]; Epstein [@CR44]).

Adeno-associated virus {#Sec3}
======================

Adeno-associated viruses (AAV) are parvoviruses that require co-infection with another helper virus (either adenovirus or HSV) to mediate their replication. The small non-enveloped icosahedral virions (18- to 26-nm diameters) contain a single-stranded DNA molecule (4--5 kb) that contains inverted terminal repeats (ITR) which enable site-specific integration of wild-type AAV into chromosome 19 as well as allow secondary structure formation of the viral genome that aids viral DNA replication with host cell polymerase (Ni et al. [@CR118]). The non-pathogenic and persistent long-term nature of AAV infection (Wright et al. [@CR194]), combined with its wide range of infectivity, made this virus an important candidate as a therapeutic gene transfer vector. In addition, the relatively small *cis*-acting elements (the ITRs) in AAV vectors greatly reduce the risk of recombination with wild-type virus as well as the level of cellular immune response elicited, therefore improving the safety of this vector in human clinical applications (Koczot et al. [@CR81]). Furthermore, AAV vectors have a broad host and cell type tropism transducing both dividing and non-dividing cells.

The first infectious clone of AAV serotype 2 (AA2) was established in 1982. It was used to generate the first recombinant AAV (rAAV) vectors (Hermonat and Muzyczka [@CR66]) and has therefore been studied in great detail, and many mechanisms involved in AAV integration and latency have been elucidated (Gao et al. [@CR51]). AAV2 is widely used to transduce neurons as it demonstrates neuron-specific expression. However, more recently, multiple serotypes of wild-type AAV (12 human serotypes and more than 100 serotypes from nonhuman primates), each with a different targeting capacity, have now been identified (Daya and Berns [@CR35]). Due to the diverse tissue tropisms and potential to evade preexisting antibodies against the common human AAV serotype 2, some of these AAV serotypes may have the potential to be developed as novel human gene therapy vectors (Coura and Nardi [@CR26]). The use of the different AAV serotypes in a pseudotyping approach (the genome of one ITR serotype being packaged into a different serotype capsid) has allowed broad tissue tropisms, with greater gene expression being seen in muscle, retina, liver and heart (using AAV serotypes 1, 5, 8 and 9, respectively). Studies have also examined the transduction and expression characteristics of these serotypes in brain (Cearley et al. [@CR24]), and AAV9 was shown to transduce a large number of cells with unique expression pattern. However, some tissues remain refractory to transduction using available serotypes, presenting a major challenge for AAV-based gene therapy in clinically relevant tissues. Two approaches have been employed: (1) altering the direct targeting of rAAV vectors by either the insertion of small peptides or ligands directly into the viral capsid sequence (e.g. aiding targeting of endothelial cells; Stachler and Bartlett [@CR166]; White et al. [@CR187]) or by site-directed, insertional mutagenesis of the AAV2 capsid (Muzyczka and Warrington [@CR112]; Shi et al. [@CR155]) and (2) using an associating molecule, such as a bispecific antibody (Bartlett et al. [@CR12]) or biotin (Arnold et al. [@CR5]) which interacts with both the viral surface and specific cell surface receptor and mediated indirect targeting. The latter approach enables the coupling of different adaptors to the capsid, ablating the native targeting and enhancing specific targeting without significantly changing the capsid structure.

Regardless of serotype, the production of rAAV vectors involves splitting the AAV genome between two plasmids: (1) a recombinant AAV vector plasmid where the AAV capsid genes are replaced with the gene of interest, bracketed by ITRs and (2) a non-rescuable AAV helper plasmid encoding AAV capsid proteins. The production of recombinant AAV vectors also requires a helper virus (adenovirus or HSV) which allows viral replication, and density gradient centrifugation is typically used to separate recombinant AAV vectors from the adenoviral or HSV helper.

The inclusion of ITRs in rAAV vector systems prevents integration into chromosome 19, and current rAAV vectors persist primarily as extrachromosomal elements (Afione et al. [@CR1]; Schnepp et al. [@CR150]). In addition, the small size of these vectors limits the insertion of gene expression cassettes, and gene expression is generally of slow onset due to the required conversion of the single-stranded AAV DNA into double-stranded DNA. Such limitations have been overcome by the generation of minimal expression cassettes and self-complementary AAV2 vectors, respectively. The latter enable the rate-limiting second-strand DNA synthesis to be bypassed, enhancing transduction of some organs and tissues such as liver (McCarty et al. [@CR99]), muscle (Wang et al. [@CR184]), brain (Fu et al. [@CR49]) and retina (Yang et al. [@CR201]). As a result, rAAV-based gene transfer vectors still represent one of the most promising gene therapy systems and gain increasing popularity. rAAV2 vectors have been tested in preclinical studies for a variety of diseases such as haemophilia, alpha1 anti-trypsin deficiency, cystic fibrosis, Duchenne muscular dystrophy, rheumatoid arthritis, age-related macular degeneration (Buch et al. [@CR19]) and others. The studies so far have shown that AAV-based vectors, particularly the AAV2 serotype, are safe and efficient tools for gene transfer (further information on AAV vectors was given by Professor Michael Linden during this meeting and is also published in this special edition of Journal of Cell biology and Toxicology).

Adenoviral vectors {#Sec4}
==================

Adenoviruses (Ads) have been isolated from a large number of species and tissue types, and in humans, they cause mild respiratory illnesses and gastroenteritis. Wild-type adenoviruses have a double-stranded, linear DNA genome of approximately 36 kb in length. Extensive splicing of the genome results in the production of over 50 viral proteins, 11 of which are structural virion proteins that produce the characteristic non-enveloped icosahedral protein capsid (Stewart et al. [@CR169]). The capsid consists of three main proteins: hexon, penton base and knobbed fibre proteins (which extend from the penton base). The fibre proteins differ in length depending on the serotype. There are over 100 adenoviral serotypes identified that can infect and replicate in a wide range of organs (Verma and Weitzman [@CR177]). This includes 51 human serotypes (HAd) that are classified into six distinct subgroups (A--F) based on their hemagglutination properties, oncogenic potential, genomic organisation and DNA homology (Arnberg [@CR4]; Sharma et al. [@CR153]). These subgroups exhibit distinct tissue tropism and clinical manifestations (Segerman et al. [@CR151]; Wadell et al. [@CR182]). The majority of gene transfer studies utilising adenoviral vectors are derived from human Ad serotype 5 (HAd5), although Ad vectors have been generated from other serotypes (including human Ad2, Ad7 and Ad4 as well as non-human viruses).

Infection of host cells by wild-type Ads is mediated via cell surface receptors. The efficiency of Ad binding and entry to particular cell types is directly related to the distribution of specific receptors on the cell membrane (Mentel et al. [@CR101]; Russell [@CR141]) and the affinity of the different Ad subgroups to its primary receptor. For the majority of Ad serotypes (HAd2, HAd5, subgroups A, D, E and F but not of subgroup B, as well as serotypes from non-human species), the major cell surface receptor is the Coxsackie adenovirus receptor (CAR; Bergelson et al. [@CR13]; Roelvink et al. [@CR140]). The carboxy-terminal knob domain of the fibre protein (that projects from the adenovirus capsid) binds the CAR with high affinity (Nemerow [@CR115]). Binding between a critical RGD recognition motif in the virus penton base (Stewart et al. [@CR170]) and with the secondary cellular integrin receptors, α~v~β~3~, α~v~β~5~ (Wickham et al. [@CR188]), α~v~β~1~ (Li et al. [@CR90]), α~3~β~1~ (Salone et al. [@CR145]) and α~5~β~1~ (Davison et al. [@CR34]) has also been shown to occur. Following this binding, viral internalisation proceeds via clathrin-mediated endocytosis (Wang et al. [@CR183]).

Recent studies are now elucidating additional receptors for various HAd serotypes, especially subgroup B. One main receptor is CD46, a ubiquitously expressed type I transmembrane glycoprotein that is a known receptor for a number of other human pathogen (Cattaneo [@CR23]). CD46 has been identified as a cellular receptor for the majority of subgroup B HAds, including HAd3, HAd7, HAd16, HAd21, HAd50 (subspecies B1), HAd11, HAd14, HAd34 and HAd35 (subspecies B2) (Fleischli et al. [@CR47]; Segerman et al. [@CR151], [@CR152]; Sharma et al. [@CR153]), although CD46 usage by HAd3 and HAd7 remains controversial (Marttila et al. [@CR96]; Tuve et al. [@CR176]). In addition, subgroup D HAds (e.g. HAd37 and HAd49) has also been suggested to use CD46 as an attachment receptor (Lemckert et al. [@CR86]; Wu et al. [@CR195]). Additional cell surface molecules that act directly as attachment or internalisation receptors or indirectly (assisting CAR accessibility to the Ad fibre) have also been identified (Arnberg [@CR4]). These include CD80, CD86, sialic acid, proteoglycans, major histocompatibility complex class I and vascular cell adhesion molecule I. In some cases (e.g. sialic acid), these molecules act as cellular receptors for other viruses, including influenza virus, rotavirus, cornavirus and polyomavirus (Dormitzer et al. [@CR41]; Stehle and Harrison [@CR167]; Weis et al. [@CR186]), whereas the interaction with CD80 and CD86 appears to be specific to certain adenoviral subgroups, e.g. subgroup B. Cells of hematopoietic origin and neoplastic are readily transduced by subgroup B due to high levels of CD80/86 expression (Knaan-Shanzer et al. [@CR79]; Rea et al. [@CR136]; Short et al. [@CR157]). Such research has prompted the proposal of an alternative classification of subgroup B HAds based on their receptor usage (Tuve et al. [@CR176]), and it is hoped that further understanding of subgroup B HAd internalisation will advance the design of novel Ad vectors for gene delivery. Such understanding also has implications for the usage of research models. For example, the low CD46 expression on rodent cells and low homology between human and rodent CD46 means that rodents do not serve as an ideal model for subgroup B HAds. However, CD46 transgenic mouse models that have CD46 expression profile similar to monkeys and humans have been produced to serve as a suitable preclinical model for CD46-binding Ad vectors (Sakurai et al. [@CR144]; Tatsis et al. [@CR173]).

Once inside the cell, the virus-encoded protease assists in the gradual disruption of the virus capsid by proteolysis of viral structural proteins (Greber et al. [@CR57]). This allows the partially disrupted virus to be transported to the nuclear membrane via the participation of dynein and microtubules (Leopold et al. [@CR87]). The viral particle, consisting of viral DNA and numerous other viral-encoded proteins, is then imported through the nuclear pore into the nucleus where viral-encoded proteins form a complex with the cellular nuclear matrix to facilitate initiation of the primary transcription events. The viral DNA does not under normal circumstances integrate into the host cell genome, but remains episomal within the nucleus. The Ad genome is transcribed and replicated at discrete replication centres in the nucleus of the infected cell. Ad transcription can be defined as a two-phase event, early (E) and late (L), occurring before and after DNA replication, respectively (Fig. [1](#Fig1){ref-type="fig"}). Transcription of the four early genes, E1, E2, E3 and E4, is accompanied by numerous splicing events to generate proteins required for transactivating other viral regions or for modifying the host cellular or immunological environment. Following transport into the host cell nucleus, transcription from the viral E1 gene is initiated, producing E1a and E1b proteins. E1a proteins alter cellular metabolism and activate transcription of the other E genes (Russell [@CR141]), whereas the E1b protein prevents apoptosis of the host cell, promoting oncogenesis and transformation. Together, E1a and E1b also inhibit inflammation caused by Ad infection (Schaack et al. [@CR147]). The E2 gene products interact with a number of cellular factors to enable replication of viral DNA and transcription of the L genes. In contrast, E3 gene products are non-secreted proteins that control various host immune responses by interfering with host defence mechanisms (Horwitz [@CR69]). As a result, they are not required for viral replication in culture (Russell [@CR141]) and are often deleted from Ad gene therapy vectors. The E4 gene products modulate viral gene expression and replication through interaction with host cell systems. They facilitate virus messenger RNA metabolism, provide functions to inhibit host protein synthesis and promote virus DNA replication (Leppard [@CR88]). In addition, wild-type adenoviruses also transcribe a set of untranslated RNAs (the VA RNAs) that combat cellular defence mechanisms by blocking activation of the interferon response (Mathews and Shenk [@CR97]). Following viral DNA replication, the major late promoter in the viral genome becomes fully activated (Nevins [@CR117]), initiating transcription and splicing of the major late transcription unit (MLTU) that produces five different transcripts (L1 to L5) that supply the viral capsid proteins (Farley et al. [@CR45]) and aid maturation of virus particles in the nucleus. Fig. 1Production of first-generation Ad vectors from wild-type adenovirus genome. Wild-type adenoviruses have a double-stranded, linear DNA genome of approximately 36 kb in length. It is divided into early (*E*) and late (*L*) gene transcripts. Transcription of the viral genome begins with the E1 gene, producing E1a and E1b proteins. E1a proteins alter cellular metabolism and activate transcription of the other E genes, whereas the E1b protein prevents apoptosis of the host cell, promoting oncogenesis and transformation. The E2 gene products interact with a number of cellular factors to enable replication of viral DNA and transcription of the L genes. E3 gene products control various host immune responses, and the E4 gene products modulate viral gene expression and replication. In addition, wild-type adenoviruses also transcribe a set of untranslated RNAs (the VA RNAs) that combat cellular defence mechanisms by blocking activation of the interferon response and a MLTU that produces the viral capsid proteins. The creation of first-generation replication-deficient Ad vectors involved the removal of the E1 genes. In addition, E3 genes were also removed, as they are not required for viral replication in culture. This enabled up to 8-kbp foreign DNA, encoding promoters and foreign transgenes, to be incorporated into the genome. Figure adapted from Horwood et al. Arthritis Research, [@CR61]

Initial studies using Ad vectors focused on the respiratory tract (the natural target tissue of this virus). Subsequent studies demonstrated that Ads can infect a great variety of post-mitotic cells, even those associated with highly differentiated tissues such as skeletal muscle, lung, brain and heart. In 1993, Ad vector systems were first demonstrated to be a viable means of gene transfer to the nervous system (Akli et al. [@CR2]; Davidson et al. [@CR32]). Wild-type Ads can only incorporate an additional 2 kb of foreign DNA without significant effects upon the stability of infectivity (Russell [@CR141]). Removal of viral-encoded genes allows the incorporation of larger genetic sequences. First-generation Ad vectors were produced by removing the E1 and E3 viral cassettes, making way for approximately 8 kb of foreign DNA (Bett et al. [@CR14]; Verma and Weitzman [@CR177]). The removal of the E1 gene renders the virus extremely attenuated in its ability to replicate, and it is therefore necessary to propagate these viruses in a helper cell line that supplies the E1 gene in *trans*, such as the human embryonic kidney 293 (HEK293) cell line (Graham et al. [@CR56]). The most commonly used methods to produce first-generation recombinant Ads rely on either homologous recombination in mammalian cells (Bett et al. [@CR14]), homologous recombination in bacteria (He et al. [@CR63]) or in vitro ligation (Mizuguchi and Kay [@CR105]). Following homologous recombination in HEK293 cells, viral particles are screened for those expressing the inserted transgene by plaque purification. Further modifications to this method, including alterations made to the packaging cell lines, have reduced the need for this step and increased the efficiency of adenoviral production protocols (Davidson et al. [@CR33]). Viral particles are released from HEK293 cells by sonication, separated by a CsCl gradient spin and purified by dialysis before storage. The high transduction efficiency of Ad vectors combined with their relative ease of preparation and purification has led to their extensive use as gene transfer vectors (Hermens and Verhaagen [@CR65]; Verma and Weitzman [@CR177]).

Initial in vivo studies conducted with first-generation Ad vectors revealed several limitations, including the initiation of significant systemic immune and inflammatory responses. This reduced the duration of transgene expression and limited safety and efficacy when used in vivo (Byrnes et al. [@CR22]; Muruve [@CR111]; Wilson [@CR190]). Furthermore, under certain circumstances, cellular factors can transactivate viral genes that have E1A-responsive promoters and facilitate low-level DNA replication and the production of late structural antigens. Such problems are highly apparent when first-generation Ad vectors are injected into peripheral organs (Spergel et al. [@CR163]; Spergel and Chen-Kiang [@CR162]). Transgene expression is generally undetectable after 14 days due to activation of CD8^+^ T cells that subsequently eliminate the infected cell and induce a humoral response against antigens contained in the viral capsid (Yang et al. [@CR198], [@CR200]). In addition, significant toxicity, both in vitro and in vivo, has been reported when first-generation Ad vectors are used to infect cells at higher doses (or multiplicities of infection).

To overcome such problems, extensive developments in Ad vector biology and expression cassette design have been made. Second-generation vectors were developed to address the problems of immune recognition, containing deletions in the E2a and E2b genes that encode viral DNA binding protein and DNA polymerase, respectively (Engelhardt et al. [@CR43]; Morral et al. [@CR109]; Yang et al. [@CR199]). Ad vectors deleted of E4 genes have also been investigated (Dedieu et al. [@CR37]). The resulting recombinant viral vectors can incorporate larger transgenes (up to 10 kbp), are less cytotoxic and systemically immunogenic, but are unable to produce high viral titres or mediate stable transgene expression. A significant advance in Ad vector technology has been the development of helper-dependent (Hd) or 'gutless' Ad vectors that are deleted of all Ad gene sequences except those required (in *cis*) for replication and packaging (Palmer and Ng [@CR125]). A replication incompetent (helper) virus is therefore required to supply all of the necessary Ad functions in *trans* and is later separated from the recombinant virus (Parks et al. [@CR127]). Consequently, the production of Hd-Ads is more complicated than earlier generations, with problems in the longevity and levels of expression (Schiedner et al. [@CR149]) as well as helper virus contamination (Alba et al. [@CR3]). Due to the large amount of viral DNA removed, the cloning capacity of the vector is increased and the host adaptive response is minimised. This improves the efficacy and duration of gene transfer in vivo (Muruve [@CR111]; Parks et al. [@CR127]), and long-term expression in immunocompetent animals, including efficient delivery to the CNS (Cregan et al. [@CR27]; Zou et al. [@CR202]), has been demonstrated using these vectors (Schiedner et al. [@CR148]).

Retrovirus {#Sec5}
==========

Retroviruses are RNA viruses that replicate through a DNA intermediate (Kay et al. [@CR77]). They were among the first viruses to be developed for gene therapy and have subsequently become the most commonly used RNA virus vectors. This large family of enveloped RNA viruses is found in all vertebrates, and they can be classified into oncoretroviruses, lentiviruses and spumaviruses (Verma and Weitzman [@CR177]). All retroviruses consist of a lipid-enveloped virus particle (virion) that surrounds an inner core, known as the nucleocapsid. This contains two identical copies of the viral RNA genome, reverse transcriptase, integrase and protease. The nucleocapsid is surrounded by a protein shell formed by capsid proteins enclosed by a layer of matrix proteins that interact with the lipid envelope (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Schematic of retrovirus. Retroviruses are RNA viruses that consist of a lipid envelope, depicted by the *outer ring*, which interacts with transmembrane matrix proteins and projecting receptor binding proteins. Host cell interactions are governed by these receptor binding proteins and can be altered by pseudotyping with other viral envelope proteins. The inner portion of the virion, known as the nucleocapsid, contains two identical copies of the viral genome and the viral reverse transcriptase, integrase and protease

The viral RNA forms a homodimer of linear, positive-sense, single-stranded RNA genomes containing three essential genes, *gag*, *pol* and *env*, that are flanked by long terminal repeat (LTR) sequences. These LTRs act in *cis* with neighbouring sequences during viral gene expression and packaging, retrotranscription and integration of the genome (Kay et al. [@CR77]). The *gag* gene encodes for the core proteins, capsid matrix and nucleocapsid, which are generated by proteolytic cleavage of the gag precursor protein (Verma and Weitzman [@CR177]). The *pol* gene encodes for the viral enzymes protease, reverse transcriptase and integrase. These are usually derived from the *gag-pol* precursor. Finally, the *env* gene encodes for the envelope glycoproteins, which mediate virus entry (Verma and Weitzman [@CR177]). An additional gene, the *pro* gene, encodes for the protease activity, responsible for *gag* and *gag-pol* cleavage and the maturation of the viral particles during or after budding.

Oncoretroviruses are simple viruses encoding only these three essential genes, whereas lentiviruses and spumaviruses are more complex and encode for additional viral proteins. However, all retroviruses infect cells by an interaction between specific host cell surface receptors (entry receptors) and co-receptors with viral envelope glycoproteins. The viral particle is then internalised through virus--cell membrane fusion, and the virus core is released into the cytoplasm (Verma and Weitzman [@CR177]). The viral RNA genome is reverse-transcribed into linear double-stranded pro-viral DNA by the viral enzyme reverse transcriptase. The proviral DNA associates with viral proteins (including nucleocapsid, reverse transcriptase and integrase) to form a pre-integration complex that is rapidly transported to the host cell nucleus. Virally encoded integrase mediates the integration of the provirus into the host cell genome, which is subsequently transcribed into RNA from the viral promoter contained in the 5′ LTR. This process is initiated by host cell transcription factors, and once transcribed, the viral RNA is transported to the cytoplasm where it is translated into viral proteins. The required viral structural proteins and replication enzymes (i.e. *gag-pol* and *gag* precursors) assemble with two copies of the viral RNA to form new virion cores at the plasma membrane (Verma and Weitzman [@CR177]).

The first retroviral vectors to be developed and used in a gene therapy trial were based on the 'simple' moloney murine leukaemia virus (MMLV, an oncovirus; Blaese et al. [@CR15]). Since their initial use, retroviruses have been used for stable gene transfer into mammalian cells for over 20 years (Barquinero et al. [@CR10]). They are often the method of choice as they provide lifelong expression of the introduced gene due to integration into the host cell genome. However, simple retroviruses such as MMLV require the disruption of the nuclear membrane at mitosis to grant the pre-integration complex access to the chromatin and subsequently integrate into the host cell genome (Roe et al. [@CR139]). Consequently, simple retroviral vectors are of limited use for gene transfer to post-mitotic neurons. Nevertheless, MMLV has been used to deliver genes to the brain in an ex vivo manner. For example, MMLV-mediated transfer of the tyrosine hydroxylase gene to fibroblast and astrocyte cells in culture has been demonstrated, and subsequent transplantation of these cells results in partial behavioural recovery in the 6-OHDA model of Parkinson's disease (Wolff et al. [@CR191]).

Lentivirus {#Sec6}
----------

Lentiviruses are a subgroup of the retrovirus family. Their genomes are slightly more complicated, containing accessory genes that regulate viral gene expression, control the assembly of infectious particles, modulate viral replication in infected cells and contribute to the persistence of infection (Kay et al. [@CR77]). For example, human immunodefiency virus-1 (HIV-1), a commonly used lentiviral vector, encodes six additional proteins (*tat*, *rev*, *vif*, *vpr*, *nef* and *vpu*; Frankel and Young [@CR48]; Verma and Weitzman [@CR177]). These proteins are involved with budding, maturation and integration steps of the viral life cycle, enhancing the rate of transcription and nuclear export of the viral RNA as well as assisting in the assembly of the virion (Blesch [@CR16]). In addition, lentiviral vectors do not require the breakdown of the nuclear membrane in order to integrate (Lewis and Emerman [@CR89]). The lentivirus-encoded *gag* matrix protein, integrase enzyme (Gallay et al. [@CR50]) and *vpr* protein (Heinzinger et al. [@CR64]) interact with the nuclear import machinery of the target cell and facilitate active transport of the pre-integration complex through the nucleopore. This enables transfection of non-dividing cells, and as a result, such 'complex retroviruses' have shown promise as gene transfer vectors, especially for post-mitotic cells such as neurons (Blomer et al. [@CR17]; Naldini et al. [@CR113];Vigna and Naldini [@CR178]).

Lentiviral vectors were developed by the removal of all viral genes, except those required (in *cis*) in order to complete a single round of replication. All other components are supplied in *trans* from either transient transfection or stable cell lines. HEK293T cells, a derivative of HEK293 cells that contain the SV40 large T-antigen, are often used for lentiviral production. In addition, the viral *rev* protein is provided in *trans*, as are *gag* and *pol*, achieved by co-transfection of helper cell lines (Pacchia et al. [@CR124]; Fig. [3](#Fig3){ref-type="fig"}). Following co-transfection of helper plasmids with the shuttle plasmid, expressing the foreign transgene of choice, the viral vector particles are produced and released into the media by the budding process. The resulting lentiviral vectors are then purified and concentrated by ultracentrifugation. Further advances in lentiviral vector design involving the deletion of further non-essential pathogenic genes reduced the HIV-derived packaging component of second-generation vectors to the *gag*, *pol*, *tat* and *rev* genes of HIV-1 (Delenda [@CR38]; Kim et al. [@CR78]; Zufferey et al. [@CR203]). Third-generation lentiviral vectors see the replacement of the *tat* gene with powerful constitutive promoters, such as the immediate early cytomegaly virus (CMV) promoter (Dull et al. [@CR42]; Kim et al. [@CR78]), increasing the bio-safety of these vectors. These minimal vector systems have the essential viral components segregated onto three or four separate plasmids with minimal sequence overlap. An additional safety concern of using lentiviral-based vector systems is the possibility of insertional activation of an oncogene following random integration of the vector provirus into the host genome. This problem has been addressed by the development of self-inactivating lentiviral vectors (Miyoshi et al. [@CR104]; Xu et al. [@CR196]). These vectors contain deletions in the U3 region of the 3′ LTR, which is transferred to the promoter in the 5′ LTR after reverse transcription and eliminates transcriptional activation of surrounding host genes (Logan et al. [@CR91]). Thus, recombinant lentiviral vectors are now constructed using only three HIV-1 genes: *gag*, *pol* and *rev*. The cloning vectors, into which genes of interest are placed, are devoid of all viral sequences apart from essential *cis*-acting sequences, including the LTRs and the packaging signal. The *rev* responsive element (RRE) is also included to ensure efficient nuclear export of the full-length viral RNA genome. Fig. 3Production of lentiviral vectors. Lentiviral vectors are produced by co-transfection of packaging constructs containing viral elements needed for one round of replication, together with the shuttle vector containing the transgene into a packaging cell line, e.g. HEK293T cells. The newly formed viral particles are released into the supernatant by the budding process and can be collected (harvested) and concentrated by centrifugation. Addition of viral components such as the cPPT, RRE and WPRE can enhance the production and subsequent transgene expression

Despite advances addressing safety concerns of using lentiviral vectors, there are still problems regarding limited transgene capacity, difficulties in constructing stable producer cell lines due to viral gene toxicity, and thus the inability to produce high-titre stocks. The reintroduction of other viral sequences, such as the central polypurine tract (cPPT) and the central termination sequence from the HIV pol gene, improves gene expression (Barry et al. [@CR11]; De Rijck et al. [@CR36]; Logan et al. [@CR91]). These sequences (regardless of their position within the viral vector; De Rijck et al. [@CR36]) improve translocation of the pre-integration complex, resulting in increased nuclear transduction efficiency and production of higher viral titres. Incorporation of a posttranscriptional regulatory element into lentiviral vectors increases nuclear RNA export, stabilises the viral vector mRNA and hence increases translation and transgene expression (Zufferey et al. [@CR204]).

The majority of lentiviral vector development has focused on primate lentivirus-based systems, such as HIV-1. However, other gene transfer systems based on non-primate lentiviruses, such as the feline immunodeficiency virus (FIV; Curran et al. [@CR31]; Poeschla et al. [@CR131]) and the equine infectious anaemia virus (EIAV; Olsen [@CR121]), have also been developed. Since their initial development, these systems have been optimised, producing minimal cassettes that include additional regulatory elements (similar to those used in HIV-1-based systems; Johnston et al. [@CR73]; Saenz and Poeschla [@CR142]) and have been pseudotyped with alternative envelope glycoproteins (Mazarakis et al. [@CR98]; Sinn et al. [@CR159]; Song et al. [@CR161];Wong et al. [@CR192]). These non-primate-based systems can successfully transduce dividing and non-dividing cells (Mitrophanous et al. [@CR103]) and can mediate neuronal gene expression in vivo (Azzouz et al. [@CR7]; Azzouz and Mazarakis [@CR6]; Wong et al. [@CR193]). Such systems are thought to be inherently safer, as humans are not the host of the wild-type virus, although early EIAV systems were limited by the instability of vector-derived RNA transcripts and silencing of the EIAV over time (O'Rourke et al. [@CR122]). Development of these systems has eliminated such problems, and many studies show that EIAV vectors can now transduce human cells with similar efficiency to HIV-1.

Gene therapy trials have highlighted concerns regarding the propensity for lentiviral vectors (including HIV-1) to integrate within transcriptionally active regions known as euchromatin. Genomic integration of lentiviral vector genome facilitates long-term expression as the viral sequence is replicated during mitosis. This desirable trait can also be a problem, especially when the insertion site is in close proximity to a proto-oncogene (Somia and Verma [@CR160]). In recent clinical gene therapy trials for X-linked severe combined immunodeficiency, five children developed leukaemia as a direct consequence of insertional mutagenesis (Staal et al. [@CR164]). In two cases, retrovirus integration was in proximity to the *LMO2* proto-oncogene promoter, leading to aberrant transcription and expression of *LMO2* (Hacein-Bey-Abina et al. [@CR58]). The development of non-integrating lentiviral vectors, where the viral genome remains episomal, may address such problems. Although such vectors offer a limited expression window in mitotic cells, good expression is produced in post-mitotic cells, such as neurons (Yanez-Munoz et al. [@CR197]). Initial studies using non-integrating lentiviral vectors have indicated that they are able to efficiently replicate and express the transgene (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Non-integrating lentiviral vectors. Modification of lentiviral plasmids to contain an integrase negative helper plasmid have enabled the development of non-integrating lentiviral vectors. The viral genome does not integrate into the host genome but remains episomal. Transduction with EGFP-expressing virus demonstrates the efficiency of these vectors: **a** Integrating lenti-CMV-EGFP, **b** non-integrating CMV-EGFP and **c** non-integrating synapsin-EGFP
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Various modifications have been employed in an effort to improve the targeting of viral vectors to specific cells and regulate transgene expression. Improved targeting has primarily been achieved by pseudotyping, altering the uptake of viral particles into specific cells by altering viral surface proteins/envelope proteins to that of another viral subtype. Such retargeting of Ad vectors away from its primary receptor (CAR) to a tissue- or cell-specific receptors has been achieved by utilising different serotypes of adenovirus (Havenga et al. [@CR62]). In addition, some rare HAd serotypes (Stone and Lieber [@CR172]) and non-human Ads (Bangari and Mittal [@CR9]) are now also being developed and investigated as alternate vectors for gene delivery. In addition to pseudotyping, targeting can be altered by specifically altering the viral capsid proteins by mutations, genetically modifying the fibre and knob fibre proteins (Bakker et al. [@CR8]; Nicklin et al. [@CR119]). Such modifications can (1) increase the tropism of Ad vectors, making cells normally refractory to transduction (due to low CAR expression) accessible targets; (2) restrict transduction to the organ of interest enabling a lower dose to be used and (3) limit transgene transcription to certain cell types. Various studies have now demonstrated that the incorporation of additional RGD motifs on Ad fibre knobs can enhance the Ad transduction to a wide variety of cells (including endothelial cells, smooth muscle, fibroblasts, numerous tumour cell types and dendritic cells) that express low levels of CAR but high levels of integrins (Okada et al. [@CR120]; Staba et al. [@CR165]; Wickham et al. [@CR189]). In addition, manipulation of such motifs may minimise the innate immune response by limiting vector interaction with the reticuloendothelial system, potentially avoiding the effects of an anti-adenoviral neutralising antibody response, and reduce the enhanced tropism for hepatocytes often displayed by Ad vectors. The latter is due to binding of coagulation factor IX, complement component C4-binding protein and vitamin K-dependent blood coagulation factors (FVII, FIX, FX and protein C) to the Ad fibre knob or hexon protein which then acts as a link for virus uptake by hepatocytes through heparan sulfate proteoglycan or LDL receptor-related protein (Arnberg [@CR4]; Parker et al. [@CR126]; Waddington et al. [@CR181]). Such retargeting will ultimately reduce systemic toxicity, especially following peripheral administration of Ad vectors.

The targeting of lentiviral vectors has been modified in a similar way, utilising the envelope proteins of various retroviruses to enhance targeting to a particular cell type (Bouard et al. [@CR18] for review). Early versions of recombinant HIV vectors were of limited use due to their strict host cell tropism (CD4^+^ targets; Poznansky et al. [@CR133]; Shimada et al. [@CR156]). Pseudotyping with the vesicular stomatitis virus G (VSV-G) envelope protein substantially reduces the potential to form wild-type virus (Kafri et al. [@CR74]; Naldini et al. [@CR113]), increases viral stability and increases the host cell tropism, enabling transfection of both dividing and non-dividing cells in vitro (Kafri et al. [@CR74]; Naldini et al. [@CR113]; Reiser et al. [@CR137]) and neurons following direct injection in the brain (Naldini et al. [@CR113]). VSV-G psuedotyping is now widely used, and such vectors recently gained FDA clearance and have entered clinical application (Lu et al. [@CR92]; Manilla et al. [@CR94]). However, VSV-G can be inactivated by serum complement (DePolo et al. [@CR39]) and has been shown to be toxic following long-term infection. Recent studies have therefore investigated pseudotyping with alternative glycoproteins (GPs) derived from other viruses, each with specific advantages and disadvantages (Cronin et al. [@CR28]). Examples include pseudotyping with rabies, Ebola Zaire (EboZ), lymphocytic choriomeningitis virus (LCMV), alpha viruses, Sindbis virus and Hantavirus glycoproteins. Both HIV-1 lentiviral and EIAV vectors have been successfully pseudotyped with various rabies virus glycoproteins (Conzelmann et al. [@CR25]; Mebatsion et al. [@CR100]; Mitrophanous et al. [@CR103]; Mochizuki et al. [@CR106]). These glycoproteins enable retrograde transport of transgene expression along nerve tracts and into distal brain areas (Wong et al. [@CR192]). MLV-based retroviral vectors pseudotyped with the LCMV GP have been shown to efficiently transduce fibroblasts, epithelial cells, hematopoietic cells, as well as hepatoma, neuroblastoma and glioma cell lines (Miletic et al. [@CR102]). FIV LCMV-WE pseudotypes are potentially useful for targeting neural stem/progenitor cells in vivo. Several reports describing successful pseudotyping of lentiviral vectors with GP from alpha viruses (river virus (RRV), Semliki forest virus and Sindbis virus) have also been described. RRV-pseudotyped FIV vectors (RRV/FIV) predominantly transduced the liver of recipient mice with a 20-fold higher transduction efficiency than that achieved with a VSV-G pseudotype that caused less cytotoxicity. Non-hepatocytes (mainly Kupffer cells) were also transduced, and following injection into the brain, RRV/FIV preferentially transduced neuroglial cells (astrocytes and oligodendrocytes; Kang et al. [@CR76]). Intravenous injection of oncoretroviruses and lentiviruses pseudotyped with a modified chimeric Sindbis virus shows high targeting specificity and low nonspecific infectivity in liver and spleen (Morizono et al. [@CR108]). Successful pseudotyping of HIV-1 vectors using Marburg virus and EboZ virus-derived virion GPs has also been described. Such vectors were more efficient in transducing myocytes, and EboZ pseudotyped vectors injected into muscle in utero were found to transduce muscle satellite or stem cells and lead to transgene expression in newly regenerated muscle after injury (MacKenzie et al. [@CR93]). Direct brain injection of EboZ/HIV pseudotypes in adult mice failed to transduce cells in the brain (Watson et al. [@CR185]). This may be due to the lack of the proper receptor in the CNS. However, EboZ pseudotypes were able to efficiently transduce the apical surface of airway epithelia after apical application (Kobinger et al. [@CR80]), and therefore, these vectors are now being employed for cystic fibrosis studies (Sanders [@CR146]). Modified lentiviral vector pseudotyped with a strain of Hantavirus (HTNV) has also been used to improve the transduction efficiency into vascular smooth muscle and endothelial cells in vitro and in vivo (Qian et al. [@CR134]).

The physical targeting of viral vectors can also be modified by coating the virus surface with polymers such as polyethylene glycol, poly-\[*N*-(2-hydroxypropyl) methacrylamide\] or biodegradable alginate microparticles (Croyle et al. [@CR29]; Kreppel and Kochanek [@CR83]; Sailaja et al. [@CR143]). Such modifications ablate the native tropism of the vector and shield it from the host immune response whilst allowing selective targeting by the attachment of a variety of targeting ligands (peptides, proteins or antibodies) to these polymers (Kreppel and Kochanek [@CR83]; Morrison et al. [@CR110]). As mentioned previously, physical targeting of Ad vectors has been altered by the use of bispecific adaptor molecules (including bispecific antibodies or fusion proteins; Dmitriev et al. [@CR40]; Parrott et al. [@CR128]; Reynolds et al. [@CR138]). In this strategy, however, the two-component nature of bispecific molecules adds complications in manufacturing and in maintaining batch-to-batch homogeneity. Furthermore, these modifications would not be inherited by progeny virions, and therefore, genetic modification of the capsid proteins is a more favoured option at this time.

In addition to these viral particle targeting methods, tissue-specific promoters or tissue-specific regulatory elements (Nettelbeck [@CR116]) have been used to limit transgene expression to the tissue of interest. Some tissue-specific promoters investigated are glial fibrillary acidic protein (GFAP), synapsin, muscle creatine kinase (MCK), phosphoglycerate kinase and neuronal-specific enolase (NSE). Muscle-specific expression has been achieved using the MCK promoter in both adenoviral and lentiviral systems (Ferrari et al. [@CR46]; Larochelle et al. [@CR84]). AAV9 vectors containing the Desmin promoter have also been used to produce gene expression in cardiac and skeletal muscle following systemic vector administration (Pacak et al. [@CR123]). Bone-specific expression has been achieved using the murine leukaemia virus long terminal repeat promoter (RhMLV; Phillips et al. [@CR130]) or the human osteogenic promoter osteocalcin (Kofron and Laurencin [@CR82]). One major field of research has focused on brain-specific expression. Several promoters have been tested for targeting to the CNS using AAV vectors (Terzi and Zachariou [@CR174]). These include CMV, NSE, platelet-derived growth factor-b and CMV-chicken β-actin (Shevtsova et al. [@CR154]). Similar studies have been performed using Ad and lentiviral vectors (Jakobsson et al. [@CR72]; Virta et al. [@CR179]). Cell specificity achieved by particular promoters can vary between different CNS regions (Peel et al. [@CR129]). GFAP promoter has been shown to drive exclusive transduction in spinal cord, hippocampal and striatal neurons. The synapsin promoter has also been utilised in Ad, lentiviral and AAV vectors systems to drive neuron-specific expression (Glover et al. [@CR55]; Nathanson et al. [@CR114]; Peel et al. [@CR129]; Sims et al. [@CR158]; Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Neuron-specific expression using the synapsin promoter. Modification of adenoviral vectors using tissue-specific promoters to produce specific expression in embryonic rat organotypic brain cultures: **a** Ad-CMV-EGFP results in ubiquitous expression. **b** Ad-Syn-EGFP vectors, containing the human synapsin promoter, produces neuron-specific expression

Viral vector utility has also been improved by the incorporation of regulatable expression systems, such as tetracycline (Harding et al. [@CR60]) and RU486 (Burcin et al. [@CR21]) inducible systems. Tetracycline inducible systems have produced highly regulatable Ad vectors (Harding et al. [@CR59], [@CR60]), allowing transgene expression to be switched on and off in vivo by the simple addition of doxycycline (a tetracycline analog) in drinking water. Such systems can enable the production of vectors that contain toxic inserts, acting specifically and at high levels in the "On" state, and show dose-responsive expression allowing varied levels of gene expression. Subsequent studies have combined this system with cell-specific promoters to drive neuron-specific and glial-specific regulatable transgene expression (Glover et al. [@CR54], [@CR55]; Lee et al. [@CR85]; Ralph et al. [@CR135]). The well-characterised tetracycline-based regulatable systems have also been utilised in lentiviral vector design (Kafri et al. [@CR75]) and AAV-based studies (Stieger et al. [@CR171]). Such lentiviral systems have already been used to mediate regulated delivery of genes thought to alleviate symptoms of Parkinson's disease (Georgievska et al. [@CR52]; Vogel et al. [@CR180]).

A range of viral vectors are therefore available to aid research, each suited for different purposes/applications due to their individual characteristics. Ad vectors have been greatly utilised for in vitro studies, transferring genetic material into many cell lines and cultured cell systems. Within our laboratory, they have been utilised to generate in vitro models of polyglutamine diseases in both a mouse neuroblastoma cell line and primary neurons (Fig. [6](#Fig6){ref-type="fig"}). Viral-mediated gene transfer enables the production of dose-dependant models where the level of disease protein expression (and therefore the severity of the disease state) can be modified by viral dose as well as the length of the CAG repeat tract within the expressed transgene. Expression within primary neurons has been achieved using the neuron-specific synapsin promoter to drive neuronal-enriched expression of polyQ proteins (Howarth et al. [@CR71]). Lentiviral vectors have subsequently been used to create an in vivo model of polyQ disease in rat striatum (Howarth et al. [@CR70]). The initial enthusiasm behind viral vector technologies is therefore still founded, especially in the laboratory setting where they provide a useful tool to enable the genetic manipulation of cells in vitro without the need for traditional transfection methods. The advent of lentiviral vectors has enabled the creation of 'stable' cell lines as well as an in vivo expression system with true longevity. In terms of gene therapy, many lessons have been learnt from clinical trials where problems of immune response and insertional mutagenesis have been highlighted (Staal et al. [@CR164]). Such difficulties are slowly being addressed, and further developments involving improved targeting, production, transgene expression and limitations of longevity are frequently occurring in each system. In addition, new technologies, including that of cell-based delivery of Ad vectors (Power and Bell [@CR132]), are also driving the field forward, and certain vector systems are proving instrumental in clinical breakthroughs. Of particular note are the advances in glioma therapy utilising HSV vectors (Markert et al. [@CR95]; Todo [@CR175]) and the development in AAV vectors (Buning et al. [@CR20]; Monahan and Samulski [@CR107]), including clinical trials for retinal therapy (Buch et al. [@CR19]). Fig. 6Utilising viral vectors to create models of polyglutamine disease. **a** SBMA model in mouse neuroblastoma cell line. Transduction of mouse neuroblastoma cells, N2a's, with adenoviral vectors expressing the androgen receptor construct that contains an expanded polyglutamine (CAG) repeat tract, leads to the development of protein aggregates within the cytoplasm upon testosterone addition. **b** Adenoviral vectors are used to create a model of polyglutamine in dissociated primary cortical neurons. These viruses express polyQ construct tagged with EGFP, driven by the synapsin promoter to enhance neuron-specific expression. **c** A similar model is also produced following the transduction of dissociated primary cortical neurons with adenoviral vectors expressing huntingtin with 103 PolyQ repeats fused to EGFP. **d** Lentiviral vectors expressing the polyQ-EGFP constructs are injected into rat striatum to create an in vivo model of polyglutamine disease

This review is based upon the talk given at ETCS-UK 1 day Symposium on Genetic Manipulation of Cells. I would like to thank them for their invitation. I also thank Drs. Stephen Kelly and Liang Fong Wong for the critical reading of this manuscript. All work presented from our laboratory has been funded by the Wellcome Trust and BBSRC.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
